Completed PHASE2 INTERVENTIONAL 1-arm NCT01156909

B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome

B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment

Sponsor: Haukeland University Hospital

Conditions Chronic Fatigue Syndrome Myalgic Encephalomyelitis

Interventions Rituximab

Updated 6 times since 2017 Last updated: Aug 29, 2014 Started: Oct 31, 2010 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Fatigue Syndrome and Myalgic Encephalomyelitis, this trial is completed. The trial is conducted by Haukeland University Hospital and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Haukeland University Hospital

Data source: Haukeland University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bergen, Norway